US-based biopharmaceutical company Conduit Pharmaceuticals has teamed up with Sarborg to use its advanced artificial intelligence (AI) and cybernetics platform.
Sarborg is engaged in the development of predictive tools through advanced cybernetics and machine learning technologies.
Under the partnership, Conduit will obtain a permanent, non-exclusive, royalty-free, and assignable right to use any platform or technology developed by Sarborg.
The company aims to evaluate key deliverables across its operations, including drug repurposing, drug discovery, solid-form identification, and clinical trial monitoring.
Conduit Pharmaceuticals CEO David Tapolczay said: “By incorporating Sarborg’s cutting-edge AI and cybernetics platform, Conduit is taking a bold step forward in revolutionising our approach to drug development and asset management.
“This partnership will provide us with a strategic advantage, allowing us to identify and act on opportunities more swiftly and accurately than ever before.”
Through the partnership, Conduit aims to address longstanding challenges in the pharmaceutical sector by reducing human error in critical decision-making processes.
The biopharma company will integrate Sarborg’s algorithmic AI and cybernetics technology to enhance efficiency, reduce costs, and advance timelines.
The approach would minimise human intervention, optimise the drug development cycle, and provide Conduit with a substantial competitive edge.
Conduit said the partnership will provide access to advanced predictive models and dashboards to evaluate drug candidates, simplify trials, and optimise asset management.
In combination with learning algorithms, the new solutions will help the company make quick, and more accurate decisions, with improved efficacy and reduced costs.
Also, Sarborg will provide continuous support to advance AI solutions with Conduit’s needs, driving long-term innovation in regulatory strategy and clinical trial monitoring.
